Viral hepatitis C

Czepiel, Jacek; Biesiada, Grażyna; Mach, Tomasz

doi:10.20452/pamw.542

Cited by 14 publications

(35 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One of the major health problems today is the viral hepatitis caused by HCV, because this virus has spread worldwide, it has different routes of transmission, and there is no efficient therapy. (1) In 2010, there were approximately 34 million people living with human immunodeficiency virus (HIV). (2) About 14,000 new HIV infections occur globally every day, 95% of which are in developing countries.…”

Section: Introductionmentioning

confidence: 99%

Hepatitis C virus infection in HIV positive attendees of Shiraz behavioral diseases consultation center in southern Iran

Davarpanah

Khademolhosseini

Rajaeefard³

et al. 2013

Indian J Community Med

View full text Add to dashboard Cite

Objective:To determine the prevalence of HCV co-infection and its correlation with demographic and risk factors among human immunodeficiency virus (HIV)-infected individuals attending Shiraz behavioral diseases consultation (SBDC) Center in southern Iran.Materials and Methods:In a cross-sectional study, 226 consecutive HIV-positive patients who referred to SBDC Center from April 2006 to March 2007 were interviewed face-to-face to record demographic data and risk factors of HIV transmission. A 10ml sample of venous blood was drawn from every subject and tested for HCV-antibodies by third generation enzyme linked immunosorbant (ELISA) and recombinant immunoblot assays (RIBA). All samples were also analyzed by qualitative reverse transcriptase polymerase chain reaction (RT-PCR) for detection of HCV-RNA.Results:The study population consisted of 214 men (94.7%) and 12 women (5.3%) with a mean age of 35.6 ± 7.9 years. The most prevalent risk factor was imprisonment (88.9%) followed by injecting drug use (79.2%). The prevalence of HCV infection was 88.5% by ELISA and 86.7% by RIBA, while HCV viremia was detected in 26.1% of the patients. HCV-antibody positivity was significantly associated with gender, age, marital status, occupation, injecting drug use, and history of imprisonment. It was inversely related to having an infected or high risk sexual partner. In the logistic regression model, the predictors of HCV-positivity were injecting drug use (OR = 24.9, P = 0.004) and imprisonment (OR = 21.4, P < 0.001).Conclusions:Prevalence of HCV infection among HIV-positive individuals in our region is very high and there is a need for stricter preventive actions against transmission of HCV among this group of patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Hepatitis C virus infection in HIV positive attendees of Shiraz behavioral diseases consultation center in southern Iran

Davarpanah

Khademolhosseini

Rajaeefard³

et al. 2013

Indian J Community Med

View full text Add to dashboard Cite

show abstract

“…The various genotypes and subtypes of HCV have been associated with different geographical spread patterns. HCV genotyping is of crucial importance in the determination of the treatment protocols and the follow-up of the clinical course since treatment success rate is low and the duration of treatment is longer in HCV genotype 1-infected patients (2). HCV genotype 1b is the most common type in the Central Anatolian Region in Turkey.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Paraoxonase 1 Activities in Patients Infected with Hepatitis C Virus Genotype 1b and Genotype 4 in the Kayseri Province of Turkey

Sariguzel¹,

Karakükçü²,

Koçer³

et al. 2015

vhd

View full text Add to dashboard Cite

Amaç: Hepatit C virüs (HCV) kronik karaciğer hastalıklarının önemli bir nedenidir ve oksidatif stres ile ilişkilidir. kronik hepatit C enfeksiyonunda uygulanacak tedavi kişinin enfekte olduğu HCV genotipine bağlıdır. Genotip 1b'de prognozun kötü olduğu bilinmekle birlikte genotip 4 için yeterli veri bulunmamaktadır. Bu çalışmada, genotip 1b ve genotip 4 HCV'li hastalarda serum paraoksonaz 1 (PON1) aktivitesinin karşılaştırılması ve karaciğer fibrozisi ile gösterilen hepatik hasar ile ilişkisinin araştırılması amaçlanmıştır. Gereç ve Yöntemler: Bu çalışmaya, 49 HCV genotip 1b ve 42 HCV genotip 4 ile infekte hasta dahil edilmiştir. Serum PON1 aktivitesinin ölçümü spektrofotometrik olarak yapılmıştır. Serum trigliserid, total kolesterol, LDL, HDL, serum transaminaz ve karaciğer histolojik aktivite indeksi (HAİ) ve fibrozis skorları retrospektif olarak değerlendirilmiştir. Bulgular: Serum PON1 aktivitesi, genotip 1b ile infekte hastalarda (147,6±73,9U/L) genotip 4 ile enfekte hastalara (192,6±99,0 U/L) göre daha anlamlı olarak düşük bulunmuştur (p=0,015). Serum PON1 aktivitesi ile HCV RNA viral yük ve fibrozis skorları arasında anlamlı korelasyon bulunmamıştır (p>0,05). Her iki genotipin diğer serum parametreleri arasında istatistiksel olarak anlamlı bir fark olmadığı gösterilmiştir (p>0,05). Sonuç: Antioksidan enzim olan PON1 aktivitesi, HCV genotip 1b ile enfekte hastalarda HCV genotip 4 ile enfekte hastalara göre daha düşük olarak saptanmıştır. Bu durum prognozu ve tedaviye cevabı etkileyebilir. PON1 prognostik bir faktör olarak kullanılacaksa HCV genotipleri ile arasındaki ilişkiyi incelemek için daha geniş bir hasta popülasyonunda yapılmış ileri çalışmalara ihtiyaç vardır.

show abstract

“…The hepatitis C virus (HCV) infects up to 170 million people throughout the world, causing chronic liver disease, inflammation, and long-term complications [1-3]. HCV is a member of the Flaviviridae family, has single-stranded RNA, and is relatively small (55 nm - 65 nm) [1-4].…”

Section: Introductionmentioning

confidence: 99%

“…HCV is a member of the Flaviviridae family, has single-stranded RNA, and is relatively small (55 nm - 65 nm) [1-4]. In 1989, it was determined that HCV is responsible for most transfusion-associated non-A and non-B hepatitis infections [2,5].…”

Section: Introductionmentioning

confidence: 99%

Current status and future directions in the management of chronic hepatitis C

Aman

Mousa

Shiha³

et al. 2012

Virol J

View full text Add to dashboard Cite

Hepatitis C virus (HCV) is endemic worldwide, and it causes cirrhosis and other complications that often lead to death; nevertheless, our knowledge of the disease and its mechanisms is limited. HCV is most common in underdeveloped nations, including many in Africa and Asia. The virus is usually transmitted by parenteral routes, but sexual, perinatal, and other types of transfer have been known to occur. Approximately 80% of individuals who contract hepatitis C develop a chronic infection, and very few are able to spontaneously clear the virus. Because hepatitis C is asymptomatic in the majority of patients, the presence of HCV RNA in the serum is the best diagnostic tool. Although serious complications from hepatitis C may not occur for 20 years, 1/5 of chronic patients eventually develop life - threatening cirrhosis. More research is needed on the different therapy options for the disease, and many factors, most importantly the genotype of the virus, must be taken into account before beginning any treatment. As there is no vaccine against HCV at present, the most effective and recommended therapy is pegylated-interferon-α-2a plus ribavirin. While interferon is marginally effective as a monotherapy, both adding the moiety and combining it with ribavirin have been shown to dramatically increase its potency. While there are numerous alternative and complementary medicines available for patients with hepatitis C, their efficacy is questionable. Currently, research is being done to investigate other possible treatments for hepatitis C, and progress is being made to develop a vaccine against HCV, despite the many challenges the virus presents. Until such a vaccination is available, prevention and control methods are important in containing and impeding the spread of the virus and mitigating its deleterious effects on the health of people and communities worldwide.

show abstract

Viral hepatitis C

Cited by 14 publications

References 18 publications

Hepatitis C virus infection in HIV positive attendees of Shiraz behavioral diseases consultation center in southern Iran

Hepatitis C virus infection in HIV positive attendees of Shiraz behavioral diseases consultation center in southern Iran

Evaluation of Paraoxonase 1 Activities in Patients Infected with Hepatitis C Virus Genotype 1b and Genotype 4 in the Kayseri Province of Turkey

Current status and future directions in the management of chronic hepatitis C

Contact Info

Product

Resources

About